Research
Hormonal
Obesity as a treatment indication was associated with a higher likelihood of achieving a 10% or greater weight reduction (AOR, 2.46).
Patients with obesity may experience better weight loss outcomes compared to those with type 2 diabetes.
StrongSupportsmedium confidence
Obesity as a treatment indication vs T2D (AOR, 2.46 [95% CI, 1.83-3.30]).
Why this rating
Based on a large retrospective cohort study.
Source
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
Hamlet Gasoyan et al. · JAMA Network Open · 2024
DOI 10.1001/jamanetworkopen.2024.33326
cohort · n=3389Cited 58×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →